Tacedinaline (Synonyms: N-acetyldinaline; CI-994; Goe-5549)

目录号: HY-50934 纯度: 99.32%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Tacedinaline (N-acetyldinaline) 是组蛋白脱乙酰酶(HDAC)的抑制剂，抑制重组 HDAC 1, 2 和 3 的 IC₅₀ 值分别为 0.9，0.9，1.2 μM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Tacedinaline Chemical Structure

CAS No. : 112522-64-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥440	In-stock
1 mg	￥125	In-stock
5 mg	￥250	In-stock
10 mg	￥400	In-stock
50 mg	￥1200	In-stock
100 mg	￥2000	In-stock
200 mg	￥3400	In-stock
500 mg	现货	询价
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

MCE 顾客使用本产品发表的 6 篇科研文献

Tacedinaline 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HDAC 亚型特异性产品:

查看所有亚型

HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Tacedinaline (N-acetyldinaline) is an inhibitor of the histone deacetylase (HDAC) with IC₅₀s of 0.9, 0.9, 1.2 μM for recombinant HDAC 1, 2 and 3 respectively.

IC₅₀ & Target^[1]

HD1

0.9 μM (IC₅₀)

HD2

0.9 μM (IC₅₀)

HD3

1.2 μM (IC₅₀)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A-375	IC₅₀	11.29 μM Compound: CI994	Antiproliferative activity against human A375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
A-375	IC₅₀	11.29 μM Compound: CI994	Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
A-375	IC₅₀	11.3 μM Compound: Tacedinaline	Antiproliferative activity against human A375 cells after 72 hrs CCK8 assay Antiproliferative activity against human A375 cells after 72 hrs CCK8 assay	[PMID: 30108928]
A-375	IC₅₀	9.64 μM Compound: 5; CI994	Antiproliferative activity against human A375 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
A549	IC₅₀	10.17 μM Compound: 2	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
A549	IC₅₀	15.96 μM Compound: CI-994	Cytotoxicity against human A549 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay Cytotoxicity against human A549 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay	[PMID: 31223439]
A549	IC₅₀	16.45 μM Compound: 5; CI994	Antiproliferative activity against human A549 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
A549	IC₅₀	20.1 μM Compound: CI994	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
A549	IC₅₀	20.1 μM Compound: 6; CI994	Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
A549	IC₅₀	20.1 μM Compound: Tacedinaline	Antiproliferative activity against human A549 cells after 72 hrs CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs CCK8 assay	[PMID: 30108928]
Epithelial cell	IC₅₀	> 50 μM Compound: 18, pfizer,CI-994	Cytotoxicity against human mammary epithelial cells by MTT assay Cytotoxicity against human mammary epithelial cells by MTT assay	[PMID: 17941625]
HCT-116	IC₅₀	10 μM Compound: 5; CI-994	Cytotoxicity in human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity in human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28885834]
HCT-116	IC₅₀	4 μM Compound: 18, pfizer,CI-994	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 17941625]
HCT-116	IC₅₀	6.39 μM Compound: 5; CI994	Antiproliferative activity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
HCT-116	IC₅₀	7.71 μM Compound: CI994	Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
HCT-116	IC₅₀	7.71 μM Compound: CI994	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
HCT-116	IC₅₀	7.71 μM Compound: 6; CI994	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
HCT-116	EC₅₀	8.4 μM Compound: Cl-994	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by cell-titer glo assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by cell-titer glo assay	[PMID: 35293758]
HCT-116	IC₅₀	9.83 μM Compound: 2	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
HeLa	IC₅₀	1.81 μM Compound: 5; CI994	Inhibition of HDAC in human HeLa cell nuclear extract assessed as decrease in deacetylation of FLUOR DE LYS Green substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay Inhibition of HDAC in human HeLa cell nuclear extract assessed as decrease in deacetylation of FLUOR DE LYS Green substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay	[PMID: 31103900]
HeLa	IC₅₀	1.81 μM Compound: CI994	Inhibition of HDAC in human HeLa cell nuclear extract using fluor-de-lys-green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract using fluor-de-lys-green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay	[PMID: 31003060]
HeLa	IC₅₀	13.43 μM Compound: 5; CI994	Antiproliferative activity against human HeLa cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
HeLa	IC₅₀	18.02 μM Compound: CI994	Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
HeLa	IC₅₀	18.78 μM Compound: CI994	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
HepG2	IC₅₀	10 μM Compound: 5; CI-994	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28885834]
HepG2	IC₅₀	18.5 μM Compound: Tacedinaline	Antiproliferative activity against human HepG2 cells after 72 hrs CCK8 assay Antiproliferative activity against human HepG2 cells after 72 hrs CCK8 assay	[PMID: 30108928]
HepG2	IC₅₀	18.51 μM Compound: 6; CI994	Antiproliferative activity against human HepG2 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human HepG2 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
LNCaP	IC₅₀	7.4 μM Compound: 3, CI-994	Antiproliferative activity against human LNCap by MTT assay Antiproliferative activity against human LNCap by MTT assay	[PMID: 18166465]
MCF7	IC₅₀	13.16 μM Compound: 2	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
MDA-MB-231	GI₅₀	0.17 μM Compound: 1	Growth inhibition of human MDA-MB-231 cells after 5 days by MTT assay Growth inhibition of human MDA-MB-231 cells after 5 days by MTT assay	[PMID: 18543902]
MGC-803	IC₅₀	11.6 μM Compound: CI994	Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
MGC-803	IC₅₀	11.6 μM Compound: 6; CI994	Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
NCI-H1299	IC₅₀	33.79 μM Compound: CI994	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
NCI-H1299	IC₅₀	33.8 μM Compound: Tacedinaline	Antiproliferative activity against human H1299 cells after 72 hrs CCK8 assay Antiproliferative activity against human H1299 cells after 72 hrs CCK8 assay	[PMID: 30108928]
NCI-H1299	IC₅₀	6.79 μM Compound: 2	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
NCI-H460	IC₅₀	9.7 μM Compound: Tacedinaline	Antiproliferative activity against human H460 cells after 72 hrs CCK8 assay Antiproliferative activity against human H460 cells after 72 hrs CCK8 assay	[PMID: 30108928]
NCI-H661	IC₅₀	20 μM Compound: CI-994	Antiproliferative activity against human NCI-H661 cells after 48 hrs Antiproliferative activity against human NCI-H661 cells after 48 hrs	[PMID: 18692397]
NIH3T3	IC₅₀	9.05 μM Compound: CI994	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 31003060]
NIH3T3	IC₅₀	9.05 μM Compound: 5; CI994	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
PC-3	GI₅₀	0.29 μM Compound: 1	Growth inhibition of human PC3 cells after 5 days by MTT assay Growth inhibition of human PC3 cells after 5 days by MTT assay	[PMID: 18543902]
Sf9	IC₅₀	147 nM Compound: 27; CI-994	Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in Sf9 insect cells using FAM-labeled acetylated peptide A as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence ass Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in Sf9 insect cells using FAM-labeled acetylated peptide A as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence ass	[PMID: 30735902]
Sf9	IC₅₀	41 nM Compound: 27; CI-994	Inhibition of recombinant human full length C-terminal His/FALG-tagged HDAC1 expressed in Sf9 insect cells using FAM-labeled acetylated peptide A as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence Inhibition of recombinant human full length C-terminal His/FALG-tagged HDAC1 expressed in Sf9 insect cells using FAM-labeled acetylated peptide A as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence	[PMID: 30735902]
SMMC-7721	IC₅₀	> 32 μM Compound: CI994	Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
SMMC-7721	IC₅₀	14.06 μM Compound: 5; CI994	Antiproliferative activity against human SMMC7721 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
SMMC-7721	IC₅₀	16.9 μM Compound: Tacedinaline	Antiproliferative activity against human SMMC7721 cells after 72 hrs CCK8 assay Antiproliferative activity against human SMMC7721 cells after 72 hrs CCK8 assay	[PMID: 30108928]

体外研究
(In Vitro)

Tacedinaline (N-acetyldinaline) 是一种新型口服化合物，在临床前模型中具有广谱抗肿瘤活性。作用机制可能涉及抑制组蛋白去乙酰化和细胞周期停滞。Tacedinaline (N-acetyldinaline) 与常用于非小细胞肺癌细胞系管理的抗肿瘤药物联合使用，在 Tacedinaline (N-acetyldinaline) (40 μM) 和吉西他滨 (0.01 μM) 在处理 48 和 72 小时^[2]。
Tacedinaline (N-acetyldinaline) 抑制有丝分裂原刺激的血淋巴细胞增殖，IC₅₀ 值为 3 μM^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Tacedinaline (CI-994) 可在大鼠单次口服后 1 天内影响淋巴组织，这种影响通常在 7 天内可逆^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

269.30

Formula

C₁₅H₁₅N₃O₂

CAS 号

112522-64-2

性状

固体

颜色

White to gray

中文名称

乙酰地那林；他地那兰

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 50 mg/mL (185.67 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.7133 mL	18.5667 mL	37.1333 mL
5 mM	0.7427 mL	3.7133 mL	7.4267 mL
10 mM	0.3713 mL	1.8567 mL	3.7133 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.28 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.32%

选择批次：

Data Sheet (637 KB) SDS (393 KB)

COA (191 KB) HNMR (122 KB) LCMS (80 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Moradei OM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. [Content Brief]

[2]. Loprevite M, etal. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15(1):39-48. [Content Brief]

[3]. LoRusso PM, et al. Preclinical antitumor activity of CI-994. Invest New Drugs. 1996;14(4):349-56. [Content Brief]

[4]. Graziano MJ, et al. Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Arch Toxicol. 1999 Apr-May;73(3):168-74. [Content Brief]

Animal Administration ^[4]	Rats: To characterize the effects of Tacedinaline (CI-994) on lymphoid tissue, male rats are administered single oral doses at 0 (vehicle control), 10, 23, and 45 mg/kg and killed up to 7 days after dosing for evaluation of white blood cell differentials, bone marrow differentials, lymphoid tissue weights, and selected histopathology of lymphoid tissue^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Moradei OM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. [Content Brief] [2]. Loprevite M, etal. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15(1):39-48. [Content Brief] [3]. LoRusso PM, et al. Preclinical antitumor activity of CI-994. Invest New Drugs. 1996;14(4):349-56. [Content Brief] [4]. Graziano MJ, et al. Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Arch Toxicol. 1999 Apr-May;73(3):168-74. [Content Brief]

Animal Administration
^[4]

Rats: To characterize the effects of Tacedinaline (CI-994) on lymphoid tissue, male rats are administered single oral doses at 0 (vehicle control), 10, 23, and 45 mg/kg and killed up to 7 days after dosing for evaluation of white blood cell differentials, bone marrow differentials, lymphoid tissue weights, and selected histopathology of lymphoid tissue^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Moradei OM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. [Content Brief]

[2]. Loprevite M, etal. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15(1):39-48. [Content Brief]

[3]. LoRusso PM, et al. Preclinical antitumor activity of CI-994. Invest New Drugs. 1996;14(4):349-56. [Content Brief]

[4]. Graziano MJ, et al. Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Arch Toxicol. 1999 Apr-May;73(3):168-74. [Content Brief]

Tacedinaline 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.7133 mL	18.5667 mL	37.1333 mL	92.8333 mL
	5 mM	0.7427 mL	3.7133 mL	7.4267 mL	18.5667 mL
	10 mM	0.3713 mL	1.8567 mL	3.7133 mL	9.2833 mL
	15 mM	0.2476 mL	1.2378 mL	2.4756 mL	6.1889 mL
	20 mM	0.1857 mL	0.9283 mL	1.8567 mL	4.6417 mL
	25 mM	0.1485 mL	0.7427 mL	1.4853 mL	3.7133 mL
	30 mM	0.1238 mL	0.6189 mL	1.2378 mL	3.0944 mL
	40 mM	0.0928 mL	0.4642 mL	0.9283 mL	2.3208 mL
	50 mM	0.0743 mL	0.3713 mL	0.7427 mL	1.8567 mL
	60 mM	0.0619 mL	0.3094 mL	0.6189 mL	1.5472 mL
	80 mM	0.0464 mL	0.2321 mL	0.4642 mL	1.1604 mL
	100 mM	0.0371 mL	0.1857 mL	0.3713 mL	0.9283 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tacedinaline112522-64-2N-acetyldinaline CI-994 Goe-5549乙酰地那林他地那兰CI994CI 994CI-994Goe5549Goe 5549Goe-5549HDACApoptosisHistone deacetylasesInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Tacedinaline (Synonyms: N-acetyldinaline; CI-994; Goe-5549)

Customer Review

MCE 顾客使用本产品发表的 6 篇科研文献

Tacedinaline 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HDAC 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Tacedinaline 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Tacedinaline (Synonyms: N-acetyldinaline; CI-994; Goe-5549)

Customer Review

Tacedinaline 相关抗体

MCE 顾客使用本产品发表的 6 篇科研文献

Tacedinaline 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HDAC 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Tacedinaline 相关抗体:

摩尔计算器

稀释计算器

Tacedinaline 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z